Open Randomized Clinical Trial to Evaluate the Effects of Intermittent Caloric Restriction in Patients With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Exclusion Criteria

• •Active oncological disease; includes patients already treated without complete remission or in current active treatment.
• •PSA 4 - 10 ng/mL and free/total PSA \< 25% or PSA \> 10 ng/mL
• •Previous prostatic biopsy in the last 5 years.
• •Treatment with prostatic phytotherapy in the last 4 weeks.
• •BPH alphablocking treatment in the last 6 weeks.
• •5-alpha-reductase treatment in the last 6 months.
• •Anticholinergic or betamimetics treatment in the last 4 weeks
• •Eating, weight management disorder or previous bariatric surgery.
• •Concurrent treatment with the following drugs in the fasting period: AAS and NSAIDs (except paracetamol).
• •Concurrent treatment with any of the following steroids: prednisolone, budesonide, dexamethasone, fluidcortisone, hydrocortisone or prednisone.
• •Major mental illness, which does not allow informed consent.
• •Previous cardiovascular event in the last 12 months.
• •Liver, gastrointestinal, renal or severe previous endocrine or decompensated disease in the last 12 months.
• •Presence of significant vesical lithiasis.
• •Type I diabetic patients
• •Type II diabetic patients in treatment with sulfonylureas and sodium-glucose cotransport inhibitors, as well as in patients with insulin therapy.
• •Loss of patient follow-up
• •Non-compliance with protocol procedures.